Meet us

Gubra will attend Obesity & Weight Loss Drug Development Summit Europe on October 28–29, 2026 in Munich, Germany.

The Obesity & Weight Loss Drug Development Summit Europe is organized by Hanson Wade. It focuses on the next generation of weight-loss therapeutics beyond first-generation GLP-1s, including new targets, combination therapies, tolerability, muscle preservation and more convenient dosing. It is aimed at drug developers, most of them director level or above.

Gubra will attend AASLD – The Liver Meeting on November 5–9, 2026 in Denver, CO.

The Liver Meeting is the annual meeting of the American Association for the Study of Liver Diseases (AASLD). It presents research and clinical advances in hepatology and opens with a postgraduate course. More than 2,900 abstracts have been released for the 2026 meeting at the Colorado Convention Center.

Gubra will attend Drug Discovery Chemistry Europe 2026 on November 10–12, 2026 in Barcelona, Spain.

Drug Discovery Chemistry Europe is organised by Cambridge Healthtech Institute (CHI) and takes place at the InterContinental Barcelona. The programme covers lead generation, AI and machine learning in drug discovery, next-generation protein degraders and protein-protein interactions, including small molecules and peptides that target them.

Gubra is attending the CBMR innovation Summit and Markus Rohrwild, CEO of Gubra will speak Nov 12th on “From discovery to differentiated medicines: Gubra’s unique business model for continuous innovation.

The summit is hosted by the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, at Comwell Copenhagen Portside in Nordhavn. Over three days, leaders from academia, biotech, pharma and healthcare meet for keynotes, talks and panel debates on the next generation of prevention and treatment for cardiometabolic disease.

A deep dive into Gubra’s differentiated innovation model, pipeline, and 2030 strategy.
October 27, 2026 · 1.00–5.00 pm GMT · London (2 Stonecutter Street) or via Webcast.

Presentaion (PDF)

Gubra will attend Obesity Week on November 14–17, 2026 in Washington, DC.

ObesityWeek is the annual meeting of The Obesity Society. It covers obesity science and care from basic and translational research to clinical treatment, policy and population health, across six scientific tracks. It draws more than 4,300 attendees from over 60 countries. The 2026 meeting is at the Gaylord National Resort & Convention Center in National Harbor, MD, just outside Washington, DC.

Gubra will participate in the Jefferies Global Healthcare Conference in London on November 15–19, 2026.

Hosted by the investment bank Jefferies, the conference is one of Europe’s largest healthcare-dedicated gatherings. It brings together C-suite executives from listed and private healthcare companies with institutional investors for company presentations, panels and one-to-one meetings.

Gubra will attend CNS Drug Delivery Summit on December 1–3, 2026 in Boston, MA.

The CNS Drug Delivery Summit, now in its 8th edition, is organized by Hanson Wade. It focuses on technologies that improve drug exposure in the central nervous system, such as blood-brain barrier shuttles, targeted vectors, focused ultrasound and intrathecal delivery. It brings together more than 100 senior leaders from biopharma and academia.

Gubra will attend Peptide Based Therapeutics Summit Europe 2026 on December 1–3, 2026 in London, UK.

The Peptide Based Therapeutics Summit Europe is an industry meeting on the discovery and development of peptide drugs, with sessions on peptide design, delivery and formulation, and translation to the clinic.

Gubra will attend 3rd Obesity and Weight-Loss Drug Development West Coast on December 9–10, 2026 in San Diego, CA.

The Obesity & Weight Loss Drug Development Summit West is organized by Hanson Wade. It addresses practical challenges in developing obesity therapeutics, including tolerability, muscle preservation, patient adherence, precision medicine and long-term outcomes. It is aimed at senior biopharma executives working on obesity.

Gubra will attend Society on Sarcopenia, Cachexia, & Wasting Disorders (SCWD) on December 10–12, 2026 in Washington, DC.

The 19th International Conference on Cachexia, Sarcopenia & Muscle Wasting is organized by the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), a non-profit organization. It focuses on muscle wasting across conditions including cancer cachexia and sarcopenia. Over 400 clinicians and researchers from more than 45 countries attend each year.

Gubra will participate in the SEB Nordic Seminar in Copenhagen on January 13, 2027.

The SEB Nordic Seminar is SEB’s annual investor conference in Copenhagen. Around 170 Nordic listed companies present to investors from the equity and debt markets and hold one-to-one meetings with analysts and investors, with more than 1,200 participants attending.

Gubra will participate in the 45th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11–14, 2027.

Hosted by J.P. Morgan at the Westin St. Francis, the conference is the largest and best-known healthcare investment symposium of the year. It brings together healthcare and life science companies, investors and industry leaders, and the surrounding week is a focal point for partnering and business development meetings.

Gubra will attend the Keystone Drug Delivery to the Brain Symposia  on Feb 15–18, 2027 | Rimrock Banff, Emblems Collection, Banff, AB, Canada

Gubra will attend Keystone Cardiometabolism and Interorgan Crosstalk: Novel Mechanisms and Therapies on February 16–19, 2027 in Breckenridge, CO.

Organized by Keystone Symposia in partnership with the Endocrine Society, this meeting looks at how cardiovascular and metabolic diseases arise from dysfunction across the heart, liver, kidney, muscle, immune and nervous systems. Sessions cover human genetics, AI-driven target discovery, organ-to-organ signalling, the systemic effects of obesity and emerging therapies.

Gubra will attend 17th Intrinsic Capacity, Frailty & Sarcopenia Research Conference for Healthy Longevity (ICFSR 2027) on March 3–5, 2027 in Cannes, France.

ICFSR is an international research conference on frailty, sarcopenia and intrinsic capacity, organised by ANT Event International. The 2027 programme focuses on intrinsic capacity, healthy longevity and geroscience, and the conference takes place at the JW Marriott Cannes.

Gubra will attend SCOPE Summit 2027 on March 1–4, 2027 in Orlando, USA.

SCOPE Summit is an annual conference on clinical research and trial strategy, organised by Cambridge Healthtech Institute and now in its 18th year. The programme covers trial design, patient recruitment and retention, site engagement, real-world data, AI and trial operations across 38 conference tracks. It takes place at Rosen Shingle Creek in Orlando.

Gubra will attend AD/PD on March 16–20, 2027 in Barcelona.

AD/PD is the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, organized by Kenes. It covers basic, translational and clinical research on neurodegeneration, including disease mechanisms, diagnostics, drug discovery, clinical trials, new therapies such as gene therapy and immunotherapy, and prevention.

Gubra will attend MDA on March 21–24, 2027 in Orlando, FL.

The Muscular Dystrophy Association (MDA) organizes this annual conference for clinicians and researchers working on neuromuscular diseases. The program includes scientific tracks, oral and poster abstracts, industry forums and continuing education. The 2026 edition had more than 2,400 in-person and virtual attendees from 40 countries.

Gubra will attend Keystone Adipose Tissue: From Cellular Mechanisms to Systemic Health on March 21–24, 2027 in Banff.

This Keystone Symposia meeting treats adipose tissue as an active organ that shapes whole-body health. Topics include its role in metabolism, thermogenesis, immune function and hormone-like signalling, how its dysfunction contributes to obesity, cardiometabolic disease and cancer, and how incretin therapies interact with adipose biology. It runs jointly with the Incretin Biology and Therapeutics symposium.

Gubra will attend Keystone Incretin Biology and Therapeutics: Transforming Obesity and Associated Diseases on March 21–24, 2027 in Banff.

This Keystone Symposia meeting focuses on the gut hormones GLP-1 and GIP and the therapies based on them for obesity, diabetes and related diseases. Themes include central versus peripheral mechanisms, whether GIP should be activated or blocked, the quality of weight loss, targets beyond incretins, and drug design such as polyagonists and long-acting molecules. It runs jointly with the Adipose Tissue symposium.

Gubra will attend HERS Women’s Health Executive Summit on April 12–14, 2027 in San Diego, CA.

Cambridge Healthtech Institute organizes the HERS Women’s Health Executive & Research Summit. It brings together entrepreneurs, investors, MedTech and digital health teams, clinicians, payers and therapeutics R&D teams. The program has three tracks: Venture & Innovation, MedTech, and Therapeutics, which covers new drug targets, novel modalities and assays.

Gubra will attend Swiss Biotech Day on April 26–27, 2027 in Basel, Switzerland.

The Swiss Biotech Association hosts Swiss Biotech Day, an international biotech industry conference at Congress Center Basel covering R&D, manufacturing, data, AI, talent and financing. A Global Village hosts international delegations. The 2026 edition drew more than 3,500 participants from 58 countries.

Gubra will attend European Congress on Obesity (ECO 2027) and IFSO-EC Congress on May 18–21, 2027 in Munich, Germany.

The European Congress on Obesity is the annual congress of the European Association for the Study of Obesity (EASO). The 34th edition is held jointly with the 15th congress of the European Chapter of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO-EC). It covers obesity prevention, treatment and metabolic health for researchers, clinicians, surgeons, other healthcare professionals and policymakers.

Gubra will attend ERA Congress on June 3–6, 2027 in Rotterdam, The Netherlands.

The ERA Congress is the annual meeting of the European Renal Association and covers nephrology from chronic and acute kidney disease to dialysis and transplantation. The 64th edition takes place at Rotterdam Ahoy, both live and virtually. The 2025 congress drew more than 9,800 delegates.

Gubra will attend European Congress on Digital Pathology (ECDP) on June 16–19, 2027 in Rotterdam, The Netherlands.

The European Congress on Digital Pathology is organised by the European Society of Digital and Integrative Pathology (ESDIP). The 2027 edition focuses on bringing digital pathology into routine diagnostics, including AI, standardised data infrastructure and digital tools in everyday clinical practice. It brings together pathologists, researchers and industry.

Gubra will attend European Association for the Study of the Liver (EASL) on June 16–19, 2027 in London, UK.

EASL Congress is the annual meeting of the European Association for the Study of the Liver. It brings together hepatology researchers, clinicians, healthcare professionals, patient representatives and policy experts, with scientific sessions, Meet-the-Experts sessions and hands-on Skills Learning Centres. The 2026 congress drew more than 8,500 participants from over 109 countries.

Gubra will attend American Diabetes Association’s 87th Scientific Sessions on June 18–21, 2027 in Washington, D.C., USA.

The Scientific Sessions are the annual scientific meeting of the American Diabetes Association, covering research, prevention and care in diabetes. The meeting brings together more than 12,000 researchers and clinicians each year, including physicians, nurses, endocrinologists and dietitians. The 2027 meeting is at the Walter E. Washington Convention Center.

Gubra will attend Cerebral Vascular Biology (CVB) 16th International conference joint with The European Brain Barriers Meeting on June 20–23, 2027 in London, UK.

The 16th International Conference on Cerebral Vascular Biology covers the blood-brain and blood-CSF barriers and the neurovascular unit. Topics include stroke, dementia, neuroimmune dysfunction, CNS drug delivery and animal-free barrier models. It takes place at the Royal College of Physicians, with the 29th European Brain Barriers Meeting held as a satellite symposium on June 20.

Gubra will attend European Respiratory Society (ERS) on September 11–14, 2027 in Milan, Italy.

The ERS Congress is the annual congress of the European Respiratory Society, where respiratory specialists present recent advances in respiratory medicine and science. It is one of the largest events in respiratory medicine and takes place at Allianz MiCo in Milan. The society has more than 35,000 members, including clinicians, scientists and allied health professionals.

Gubra will attend European Association for the Study of Diabetes (EASD 2027) on September 20–24, 2027 in Budapest, Hungary.

The annual meeting of the European Association for the Study of Diabetes (EASD) is one of the main international congresses for diabetes research, gathering thousands of delegates. The 2027 meeting takes place at HUNGEXPO Budapest Congress and Exhibition Centre, with the scientific programme running from September 21 to 24.

Gubra will attend International Congress of Parkinson’s Disease and Movement Disorders on September 26–30, 2027 in Amsterdam, The Netherlands.

The International Congress of Parkinson’s Disease and Movement Disorders is organised by the International Parkinson and Movement Disorder Society (MDS). The programme covers more than 60 scientific topics and includes sessions with live patients, hands-on case analysis and new research. The 2026 congress received more than 2,000 abstracts.

Gubra will attend World Muscle Society on September 28 – October 2, 2027 in Helsinki, Finland.

The 32nd Annual Congress of the World Muscle Society brings together scientists and healthcare professionals working on neuromuscular physiology and diseases, from basic research to patient care. The 2024 congress, the largest to date, had 1,384 in-person attendees from 70 countries.

xGubra will attend Obesity Week on November 8–11, 2027 in Grand Rapids, MI.

ObesityWeek is the annual international conference of The Obesity Society for obesity researchers and clinicians. It covers basic and clinical research, treatment and prevention, and advocacy and public policy. Attendees include clinicians, researchers, dietitians, mental health professionals, policy specialists and industry, with more than 4,300 attendees from over 60 countries.

Gubra will attend CPHI Europe 2027 on November 9–11, 2027 in Frankfurt, Germany.

CPHI Europe is one of the largest pharmaceutical industry trade shows, organised by Informa Markets. It covers the pharma supply chain, including ingredients, contract services, manufacturing and packaging. The 2027 edition returns to Messe Frankfurt; the 2025 Frankfurt edition expected more than 60,000 visitors and over 2,000 exhibitors.